Restoration of Susceptibility of blaNDM-bearing Escherichia. coli to Carbapenem Antibiotics by Exogenous N-acetylcysteine
Dexi Li, Yuzhe Zhao, Xinyu GuoiD, Chenglong LiiD, Yage SuniD, Yixin Wang, Lijuan Chang, Xiaoming WangiD, Yanling WangiD, Štefan SchwarziD, Xiang‐Dang DuiD
Abstract
The global spread of the New Delhi metallo-{beta}-lactamase (NDM) -producing carbapenem-resistant Enterobacteriaceae pose a serious threat to public health, as NDM and its variants enzymes efficiently hydrolyze almost {beta}-lactam antibiotics. The development of novel antibiotics or antibiotic adjuvants capable of eradicating antibiotic-resistance bacteria through multiple mechanisms represents a promising strategy for reversing antibiotic resistance and preventing the emergence of new resistance. In this study, we utilized high-performance liquid chromatography (HPLC) to demonstrate that N-acetylcysteine (NAC) is a prominent reducing metabolite in bacteria harboring NDM-5. Notably, NAC was able to restore carbapenem susceptibility in NDM-producing bacteria in vitro. Subsequently, we further investigated the underlying mechanisms involved. Our findings revealed that NAC exerts its effect through multiple mechanisms that collectively contribute to reversing meropenem resistance. Firstly, NAC may inhibit biofilm formation and reduces polysaccharide production in NDM-positive Escherichia coli. and this potential mechanism was verified by transcriptomic analysis, reverse transcription PCR (RT-PCR) and a biofilm restoration experiment involving the addition of citrate cycle intermediate metabolites. Secondly, RT-PCR analysis demonstrated that NAC significantly downregulates the expression of blaNDM-5. Additionally, NAC exhibited competitive inhibition of NDM activity in vitro. Thirdly, NAC was found to enhance the intracellular accumulation of meropenem, therapy increasing its bactericidal efficacy. These three independent mechanisms offer valuable insights for developing adjuvants. The discovery offers a promising prospect for combating the antibiotic resistance concern. This study paves the way for further exploration and potential clinical applications in the fight against antibiotic-resistant bacterial infections.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Novel MBLs inhibitors screened from FDA-approved drug library restore the susceptibility of carbapenems to NDM-1-harbouring bacteria
- Trade-Offs Between Antibacterial Resistance and Fitness Cost in the Production of Metallo-β-Lactamase by Enteric Bacteria Manifest as Sporadic Emergence of Carbapenem Resistance in a Clinical Setting.
C. H. P. Cheung, M. Alorabi, … M. B. Avison·bioRxiv·Oct 24, 2020
- In-vitro and in-vivo efficacy of a novel broad spectrum β-lactamase inhibitor APC24-7 against Enterobacterales
Carina Sofia Silva Matias, Klaus Skovbo Jensen, … Jon Ulf Hansen·bioRxiv·Mar 6, 2026
- In Vitro Potentiation of Carbapenems with Tannic Acid Against Carbapenemase Producing Enterobacteriaceae: Exploring Natural Products as Potential Carbapenemase Inhibitors
A. M. Somboro, J. OSEI SEKYERE, … S. Y. Essack·bioRxiv·Jul 10, 2018
- Covalent Inhibition of New Delhi Metallo-β-Lactamases NDM-1 and NDM-5 by 3-Bromopyruvate
Jack K. Bradley, Karina Calvopiña, … Adam Paul Roberts·JAC-Antimicrobial ResistancePeer-reviewed·Jul 2, 2026
- Copy number of the blaNDM-1 gene (New Delhi metallo-β-lactamase-1) and meropenem susceptibility in Enterobacterales: Consideration for treatment with meropenem?
Amrita Bhattacharjee, Soumalya Banerjee, … Sulagna Basu·bioRxiv·Sep 3, 2025